Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,940 | 123 | 1,775 |
| Samples | 244 | 32 | 206 |
| Peptides | 248 | 28 | 220 |
Function
NF2 · NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor
This gene encodes a protein that is similar to some members of the ERM (ezrin, radixin, moesin) family of proteins that link cytoskeletal components with proteins in the cell membrane. The encoded protein is involved in regulation of contact-dependent inhibition of cell proliferation and functions in cell-cell adhesion and transmembrane signaling. The encoded protein has been shown to interact with cell-surface proteins, proteins involved in cytoskeletal dynamics, and proteins involved in regulating ion transport. Disruption of this protein's function has been implicated in tumorigenesis and metastasis. Mutations in this gene are associated with neurofibromatosis type II which is characterized by nervous system and skin tumors and ocular abnormalities. [provided by RefSeq, May 2022].
Isoforms & Proteins
11 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000338641 | P35240 | 252 | 199 |
| ENST00000397789 | P35240-3 | 229 | 186 |
| ENST00000403999 | P35240-3 | 229 | 186 |
| ENST00000361452 | P35240-5 | 218 | 175 |
| ENST00000361676 | P35240-6 | 216 | 174 |
| ENST00000403435 | P35240-8 | 213 | 175 |
| ENST00000334961 | P35240-4 | 205 | 163 |
| ENST00000353887 | P35240-4 | 205 | 163 |
| ENST00000361166 | A0A5K1VW66* | 110 | 92 |
| ENST00000413209 | P35240-9 | 62 | 54 |
| ENST00000713935 | - | 1 | 1 |
Gene Properties
Recurrent Mutations
All 199 amino-acid changes on canonical ENST00000338641 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NF2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NF2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 17/612 3% |
| Unknown | 1/10 10% | 0/29 0% |
| Cervical Carcinoma | 1/35 3% | 6/422 1% |
| Bladder Carcinoma | 2/58 3% | 12/956 1% |
| Melanoma | 2/210 1% | 25/1899 1% |
| Colorectal Carcinoma | 6/143 4% | 33/3239 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Mesothelioma | 0/62 0% | 2/165 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Meningioma | 0/3 0% | 2/252 1% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 5/1390 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Other Solid Cancers | 0/94 0% | 10/1515 1% |
| Gastric Carcinoma | 0/74 0% | 11/1809 1% |
| Hepatocellular Carcinoma | 3/46 7% | 8/2210 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Pancreatic Carcinoma | 0/89 0% | 7/1611 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Ovarian Carcinoma | 1/109 1% | 3/998 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 9/2550 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 5/1592 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Prostate Carcinoma | 0/13 0% | 6/2105 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Kidney Carcinoma | 0/85 0% | 5/1862 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Head and Neck Carcinoma | 1/85 1% | 3/1574 0% |
Mutation Distribution
Where NF2 is mutated · all tissues, split by cell line vs tissue
How many mutations in NF2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,940 mutations in NF2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|